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Tuberculosis in the Millennial Era
Onix J. Cantres-Fonseca
Abstract
Mycobacterium tuberculosis is one of the most pathogenic infectious organisms, 
usually known for causing cavitary lung infection. But this mycobacterium is 
also capable of causing masked involvement in any organ of the body. Its clini-
cal manifestation can mimic other conditions according to the organ affected. 
Extrapulmonary infection is defined as any manifestation caused by tuberculosis 
in tissues outside the airway or the pulmonary parenchyma. Despite it being a 
well-known infectious organism throughout decades, tuberculosis continues to 
be causing great morbidity and mortality in this millennium. This chapter will 
discuss the clinical manifestations of extrapulmonary tuberculosis (EPTB), when 
the mycobacteria invade extrapulmonary tissues inside the thorax. We discuss and 
review the literature about the clinical manifestations, diagnosis and evaluation, 
and general treatment.
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1. Introduction
Mycobacterium tuberculosis is one of the most pathogenic infectious organisms. 
As a single agent, it has caused more morbidity and mortality around the world 
than any other organism, despite being known for years and the emergence of 
effective antibiotic therapy. The most common form of active disease is pulmonary 
parenchymal involvement. However, with the emergence of longer life expectancy 
of immunosuppressed patients with human immunodeficiency virus and cancer, 
these mycobacteria have shown its pathogenicity causing infection outside the 
lungs, involving a great variability of extrapulmonary tissue and other organ 
systems.
Extrapulmonary tuberculosis (EPTB) occurs when the tuberculous mycobacte-
rium invades areas outside the pulmonary parenchyma, including other thoracic 
structures, and any other organ outside the lungs. Cases of extrapulmonary 
tuberculosis have been reported involving organs from the central nervous system 
throughout the abdominal organs and even the bone and skin. Clinical presenta-
tion will vary according to the organ involved, and its pathogenicity can mimic 
other infectious and noninfectious diseases. Extrapulmonary infection can be fatal 
and often requires extensive work-up for proper diagnosis. It often requires inva-
sive interventions as culture of sterile body fluids and biopsies, for evaluation of 
pathognomonic changes and identification of the mycobacteria. Also, the diagnosis 




Outside the pulmonary parenchyma, tuberculosis can invade any structure of 
the thorax, causing significant clinical disease. Involvement of any thoracic tissue, 
outside the airways and alveoli, is considered an extrapulmonary disease. Thoracic 
extrapulmonary tuberculosis includes involvement of the pleural tissue, the lymph 
nodes, the heart and blood vessels, the bone and skin, and even the complete chest 
wall. Also, tuberculosis can cause significant disease if it reaches the thoracic spine. 
This illustrates the ample spectrum of the pathology of this mycobacterium when 
it invades tissue outside the lung. Many times, therapy for thoracic extrapulmonary 
tuberculosis is similar to exclusive pulmonary involvement. However, the fact 
that extrapulmonary tuberculosis can mimic other diseases, identification of this 
mycobacteria as the culprit of a thoracic pathology, requires a vast knowledge to 
include it in the differential diagnosis. Also, thoracic extrapulmonary tuberculosis 
would require additional diagnostic and therapeutic interventions during patient’s 
management.
In this chapter, we will discuss the most important clinical manifestations of 
thoracic extrapulmonary tuberculosis. It will include the most common clinical pre-
sentations, and a review of the literature is its diagnostic and therapeutic approach.
2. Pathophysiology of thoracic extrapulmonary tuberculosis
The most common presentation thoracic extrapulmonary tuberculosis is lymph-
adenitis [1]. When the mycobacterium is inhaled into the lungs, it is engulfed by 
macrophages that activate specific T cells that protect the organism causing mostly 
latent infection. The lung natural immunity creates a granuloma around infected 
alveolar macrophages where the mycobacteria can be dormant or can proliferate. 
Depending of the bacterial load and inflammatory host response, some patients 
cannot contain the infection in the granulomas, leading to mycobacterial prolifera-
tion outside the granulomas, causing active disease [2]. The mycobacteria can also 
escape the lung throughout blood vessels and the lymphatic system invading other 
organs. In the same way, mycobacteria can invade extensively the alveolar spaces 
and reach extrapulmonary tissues after rupture of caseous foci in the proximity [3].
It is thought that most of the extrapulmonary tuberculosis occurs during pri-
mary infection rather than reactivation [4–6], especially tuberculous pleurisy [1]. 
However, in the immunosuppressed population, other extrapulmonary findings are 
more common after activation of latent disease [2].
3. Epidemiology of thoracic extrapulmonary tuberculosis
When we talk about extrapulmonary tuberculosis, we refer to any invasion of 
the mycobacteria outside the pulmonary tissue. Invasion of the pleura, thoracic 
lymph nodes, and structures of the chest wall is part of the spectrum of extrapul-
monary disease.
The most common extraparenchymal invasion of the mycobacteria in the 
thorax is invasion of the supraclavicular, mediastinal, and hilar lymph nodes [1]. 
Depending of the world location and endemicity of the infection, lymph node 
infection has been identified between 8 and 30% of the patients [1]. Almost 30% 
of those patients present with concomitant extra nodal disease [1]. Variability in 
diagnosis techniques and available resources must probably influence in the lymph 
node infection being underdiagnosed.
Tuberculous pleural involvement is the second most frequent thoracic extra-
pulmonary manifestation. Almost 25% of patients with tuberculosis present with 
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pleuritis. The incidence is higher in immunosuppressed patients secondary to 
human immunodeficiency virus [7]. The incidence of tuberculous pleural involve-
ment can be higher, but its epidemiological data is limited based on world location, 
patient population, and diagnostic resources. Pleural fluid culture has a low diag-
nostic yield, and pleural biopsy, which is the most common way for identification, 
many times is not readily available for most patients.
Heart and thoracic blood vessel involvement by tuberculosis is a rare disease. 
Diagnosis of direct cardiac tissue involvement is made in only around 2% of 
patients [8]. However, pericardial effusions are more common, and tuberculosis can 
be the culprit of most of the pericardial effusions of patient with a lack of adequate 
immune system response, reaching almost 70% of them [9]. Aortic tuberculous 
involvement is also extremely rare and can occur secondary to infection in adjacent 
tissue and blood dissemination.
Bone and chest wall infection by tuberculosis is also a rare presentation, 
accounting for approximately 2% of all tuberculosis cases reported [10]. The most 
common site of musculoskeletal involvement is the spinal bones, but tuberculosis 
can also invade the ribs, muscles, sternum, and sternoclavicular joints [10]. Most of 
the infections are also related to adjacent tissue invasion but can also occur second-
ary to hematogenous and lymphatic dissemination.
4. Tuberculous lymphadenitis
After the mycobacterium is inhaled into the lungs, it is engulfed in macrophages 
after activation of nonnatural immune system occurs. The immune system forms 
granulomas that can rupture and infect the adjacent tissue. Mycobacteria can also 
enter in the lymphatic duct and travel to the lymph node in the proximity. Inside 
the lymph nodes, the mycobacteria can cause active inflammation and abscesses. 
Tuberculous lymph node involvement can present as a mass-like lesion but also can 
cause fissures and ulcers [11]. Thoracic lymphadenitis occurs in the mediastinum 
and hilar nodes, but lymphadenopathy can also occur in the supraclavicular area 
and migrate to the neck and face. More common symptoms are those associated to 
pulmonary tuberculosis but in some patients can present with pain and mass effect. 
Other patients can present with ulceration of the skin as the nodules progress to an 
abscess and cause a fistula.
Diagnosis is made by culture and tissue evaluation. Fine needle aspiration is the 
most common diagnostic evaluation, but other techniques include surgical node 
excision. Aspiration of the lymph nodes can be done guided by ultrasound or CAT 
scan. Also, ultrasound- or non-ultrasound-guided bronchoscopic approach can also 
be done. Fine needle aspiration or direct nodal biopsy has shown similar diagnostic 
yields in the present literature [1].
Identification of the mycobacteria by acid-fast staining, cultures, and genetic 
testing has been the principal method of diagnosis. Histologic evidence of granu-
lomatous disease can also help in the diagnosis of negative culture patients in the 
proper clinical setting.
Treatment for tuberculous lymphadenitis is similar to pulmonary disease: 
antituberculous antibiotic with isoniazid, rifampin, and ethambutol for 2 
months [12], followed by 4–7 months of isoniazid and rifampin. Total duration 
of disease is about 6–9 months, and length and type of therapy can be affected 
by other organ involvement, immunosuppressive level of the patient, and 
culture sensitivities. Surgical and percutaneous drainage can assist in treatment 





Pleural tissue manifestations of tuberculosis are the second most common 
finding of thoracic extrapulmonary disease, and it competes with lymphadenitis 
as the most common extrapulmonary disease presentation. The mycobacteria can 
reach the pleural cavity by direct parenchymal tissue rupture but also can travel to 
pleural tissue by the lymphatic system. When the mycobacteria reach the pleural 
tissue, it can cause a hypersensitivity reaction that produces a lymphocytic inflam-
matory proliferation that decreases pleural fluid resorption [7]. Also, the inflam-
matory reaction increases the permeability of the pleural capillaries to proteins and 
increases the oncotic pressure inside the cavity, increasing the rate of pleural fluid 
formation [13]. The pleural fluid, rich in cells and protein, obstructs the lymphatic 
ducts of the parietal pleura and decreases fluid clearance from the pleural space 
[13]. So, a high rate of fluid formation and the decreased pleural fluid removal lead 
to the accumulation of pleural fluid and development of pleural effusions. Also, the 
inflammatory reaction and granuloma formation affect directly the pleural tissue, 
causing pleural thickening and fibrosis.
Common clinical presentations include symptoms of concomitant pulmonary 
parenchymal infection as cough, hemoptysis, fever, and weigh loss. Other patients 
present with pleuritic and nonspecific pain or dyspnea as fluid accumulation causes 
compression of the lung tissue. Chest wall pain can occur as the parietal pleura is 
involved and a pleural inflammatory reaction causes abscesses and empyema. The 
most severe presentation is when the pleural abscess fistulizes to the chest wall, 
esophagus, main bronchus, and or abdominal cavity, seen as empyema necessitans. 
Rare cases present without symptoms [14] but have been reported.
Chest images can usually present with a unilateral moderate to large pleural 
effusion, and almost 90% of patient have concomitant pulmonary parenchymal 
findings [7]. So, it is always important to rule out active pulmonary disease when 
pleural tuberculosis is suspected. Nodules, abscesses, and pleural thickening are 
also common findings on imaging.
Pleural fluid analysis during tuberculous pleurisy shows usually an exudative 
effusion. As the clinical presentation is usually subacute and chronic inflammation 
and due to the common immune reaction, the pleural fluid usually presents with 
lymphocytic cells. Pleural fluid lymphocytic predominance is mostly of more than 
50% of the total cell count, and a ratio of lymphocytes to neutrophils is in the range 
of more than 75% [15]. Cells rarely seen in pleural fluid with tuberculous involve-
ment are mesothelial cells that are present in less than 5% of the total cell count, and 
eosinophils are rarely in a proportion of more than 10% [7].
Other pleural fluid analyses show increased fluid proteins and low pH and 
glucose. Lactate dehydrogenase levels are usually high in tuberculous pleurisy, often 
higher than concomitant blood levels [7].
Pleural fluid stains for tuberculosis as the acid-fast bacillus stains are rarely 
positive. However, in immunosuppressed patients, for example, HIV positive, 
it can be positive if it is around 20% of the pleural fluid analysis [16]. Cultures 
from pleural fluid have slightly higher yield than stains, around 35%, but in 
concomitant pulmonary tuberculosis, the combination of sputum and pleural 
fluid culture can have a diagnostic yield of almost 80% [16]. Genetic testing has 
low sensitivity but good specificity [16], so a positive test is indicative of pleural 
fluid Mycobacterium tuberculosis presence, but a negative test does not rule out the 
pleural involvement.
Adenosine deaminase (ADA) is a lymphocyte-produced enzyme for metabo-
lism of the components of the DNA. ADA helps during T-cell differentiation and 
proliferation, and knowing the usual immune reaction activated by the tuberculous 
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bacilli, it is expected that ADA would be high during pleural tissue involvement. 
Levels of this enzyme have been available during years, and its use has been exten-
sively discussed. In high prevalent populations, a high level is almost diagnostic 
despite negative cultures of the mycobacterium [17]. The contrary is also considered 
correct: pleural cavity involvement can be ruled out when a patient in low-preva-
lence population has low levels of ADA in the pleural fluid. Suggested cutoff values 
for diagnosis for highly suggested disease are 65–70 IU/L. Levels of less than 35 IU/L 
have a high negative predictive value for disease in low-incidence populations [17].
Other tests that can be done for identification of tuberculous pleural effu-
sion include genetic testing with polymerase chain reaction, measurement of 
ᵞ-interferon levels, and interferon release assays. However, those tests have not been 
readily available and standardized for general use.
Pleural biopsy has the highest diagnostic yield until this time. Biopsy can be 
done using blind or image-guided percutaneous needle pleural cut. Images used to 
guide biopsy include ultrasound and CAT scan. Thoracoscopic and surgical pleural 
biopsy are more invasive alternatives. Tissue evaluation of the parietal pleural tissue 
can show caseous granuloma and the presence of acid-fast bacilli. Cultures of the 
pleural tissue have shown the highest yield (75–90%), increasing the diagnosis rate 
when the biopsy is guided by images [15].
The most efficient way of establishing a diagnosis for pleural tuberculous 
involvement is throughout a compressive and progressive evaluation. First, ruling 
out pulmonary parenchymal involvement should be done. Evaluation of the sputum 
for acid-fast bacilli and cultures is the first step. If pulmonary involvement is ruled 
out, in the presence of a lymphocytic predominant pleural effusion, pretest prob-
ability of pleural tuberculous infection must be taken into account. In low-preva-
lence populations, a low ADA (less than 35 IU/L) almost rules out the disease. In 
high-prevalence populations, a high ADA (more than 65 IU/L) is highly suggestive 
of pleural disease, and treatment can be considered. In a patient with ADA levels 
in between 35 and 65 IU/L, pleural biopsy can be done, and if typical granulomas 
are seen, therapy can be considered even with negative cultures. A positive culture 
would warrant an antibiotic therapy.
Therapy for tuberculous pleural involvement often is similar to pulmonary 
active infection, as it usually presents with concomitant disease. Usually it includes 
isoniazid, rifampin, ethambutol, and pyrazinamide for the first 8 weeks or until 
sensitivities are obtained, and then 16 weeks of isoniazid and rifampin are com-
pleted to a total of 6 months. Direct observe therapy is recommended during the 
completion of treatment [7].
Adding systemic steroids for pleural tuberculosis is not recommended as no ben-
efit has been seen [18], and usually complications of immunosuppressive therapy 
add morbidity and mortality to the patients. In some patients with persistent pain 
and fever symptoms, systemic steroids can be considered [7] for a short period of 
time, until symptoms subside. Surgical evacuation with simultaneous antitubercu-
losis antibiotics is the treatment option for empyema. It usually requires complex 
decortication and debridement of tissue and abscess area, with reconstruction of 
the surrounding tissue as in the case of empyema necessitans.
6. Cardiac and pericardial disease
Tuberculous involvement of the heart can include infection of the pericardium 
(most common), the cardiac muscle, and the large blood vessels as the aorta.
Pericardial involvement is similar to pleural tuberculosis. The pericardium 
acquires the infection by lymphatic or hematogenous spread of the bacteria, as well 
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as rupture of granulomas on an adjacent tissue. Once the mycobacteria reach the 
tissue, it causes similar hypersensitive reaction inside the pericardium leaded by T 
cells. This inflammatory process induces a granulomatous reaction that progresses 
to a fibrinous and serosanguineous effusion and produces pericardial thickening 
and fibrosis [18]. Impaired lymphatic drainage can worsen the process and cause 
rapid accumulation of fluid.
Clinical presentations can vary from systemic symptoms due to pulmonary 
and other organ infection to chest pain and congestive heart failure. Rapid fluid 
accumulation can cause vascular collapse due to cardiac tamponade. Asymptomatic 
pericardial effusion is very uncommon.
Diagnosis of pericardial involvement is made by similar mechanisms as pleural 
disease. Analysis of pleural fluid aspirated using direct visualization with ultra-
sound or CAT scan can be done. Also, surgical exploration is an alternative when 
those methods are not available, and other diseases are also considered. Pericardial 
fluid analysis findings are similar to tuberculous pleural fluid, including lympho-
cytic cellular predominance, low glucose and pH, high LDH levels, and similar 
levels of ADA. Biopsies usually show granulomas and AFB, and culture for myco-
bacteria can be positive. Empiric treatment response can be highly suggestive of 
diagnosis in high-risk populations with no conclusive diagnosis, but confirmation 
of infection is the recommended evaluation.
Other cardiac involvement presentation is direct invasion of the myocardial 
tissue and endocarditis. This is a very rare presentation and is usually fatal. Clinical 
findings include symptoms similar to a cardiomyopathy with heart failure, arrhyth-
mias, conduction blocks, cardiac output blocks, valvulopathy, and aneurysms [8]. 
Diagnosis is usually done with an autopsy due to the severity of the cases.
The aorta can also be involved after hematogenous involvement or due to 
proximity in concomitant cardiac disease. In nonfatal cases, diagnosis is done after 
reviewing tissue from repaired aneurysms [19].
Therapy for cardiac tuberculosis includes drainage of pericardial effusions, 
by surgical or percutaneous methods, with simultaneous antituberculous anti-
biotics for 6–9 months. Systemic steroids during pericardial effusion have not 
demonstrated less progression to fibrosis in the pericardium or less requirement 
of surgical interventions, but some studies suggest a decrease in mortality [20]. 
Antituberculous therapy has an initial regime of four drugs (isoniazid, rifampin, 
ethambutol, and pyrazinamide) and then two drugs, as sensitivities become avail-
able. Surgical interventions are indicated in some cases of valvular or large vessel 
involvement.
7. Bone and musculoskeletal involvement
The most common presentation of musculoskeletal involvement is vertebral 
and chest wall invasion secondary to hematogenous, lymphatic, and adjacent tissue 
infection spreading. When the spine is involved, it is known as Pott’s disease. The 
name originated from the description of tuberculous infection of the spine by Sir 
Percivall Pott, a British surgeon, in 1779 [21]. The tuberculous bacilli invade the 
bone and vertebral disk with an inflammatory and mass-like process that destroys 
the tissue causing fractures and can progress to cord compression.
Clinical presentation will vary according to deepness of tissue invasion and 
localization. Images usually show the lesions and guide the tissue diagnosis. 
Confirmation of tuberculosis involvement is done by tissue diagnosis and cultures. 
The treatment includes a similar antituberculous drug regime to other sites and 
surgery to correct possible mechanical damage.
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8. Conclusion
Thoracic extrapulmonary tuberculosis is a disease characterized for 
Mycobacterium tuberculosis involvement outside the pulmonary parenchyma and 
inside the chest cavity. It has a variety of presentations according the tissue affected. 
More common presentations include the lymph nodes and pleural tissue, but rare 
cases present with myocardial and chest wall invasion. Cases can be fatal. Therapy 
usually is mainly based on antituberculous therapy, but some patients require 
percutaneous and surgical procedures. Clinical suspicion and the correct work-up 
usually led to the diagnosis.
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